http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Genomic Profiling Shows Increased Glucose Metabolism in Luminal B Breast Cancer
Shigeto Ueda,Hideki Takeuchi,Takashi Shigekawa,Kazuo Matsuura,Noriko Nakamiya,Hiroshi Sano,Hiroko Shimada,Eiko Hirokawa,Akihiko Osaki,Toshiaki Saeki 한국유방암학회 2013 Journal of breast cancer Vol.16 No.3
We had previously reported a close association between pathological response and the maximum tumor standardized uptake value (SUVmax) measured by 18F-fluorodeoxyglucose positron emission tomography prior to chemotherapy in estrogen receptor (ER)-positive breast cancer. We hypothesized that glucose hypermetabolism by luminal B tumors may result in chemotherapy responsiveness. Using a single-gene expression assay, TargetPrint® (Agendia) and a 70-gene expression classifier,MammaPrint® (Agendia), we divided 20 patients with ERpositive primary breast cancer into luminal A and luminal B subtypes and compared the tumor SUVmax value between the two groups. A significantly higher SUVmax was measured for luminal B tumors (n=10; mean±SD, 7.6±5.6) than for luminal A tumors (n=10; mean±SD, 2.6±1.2; p=0.01). Glucose hypermetabolism could help predict intrinsic subtyping and chemotherapy responsiveness as a supplement to ER, progesterone receptor, HER2,and Ki-67 histochemical scores.